middle.news
Imugene’s Azer-cel Achieves 57% Complete Response in Tough Blood Cancer Trial
8:44am on Friday 14th of February, 2025 AEDT
•
Healthcare
Read Story
Imugene’s Azer-cel Achieves 57% Complete Response in Tough Blood Cancer Trial
8:44am on Friday 14th of February, 2025 AEDT
Key Points
Four of seven patients in Cohort B achieved complete responses
Patients had failed 4-5 prior therapies including autologous CAR T
Longest ongoing response durability at 10 months
Trial enrolling across 13 US and 5 Australian sites
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Imugene (ASX:IMU)
OPEN ARTICLE